Majid Zamani

Majid Zamani

Auto-generated profile, based on publicly available information

Majid Zamani

Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2022 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
Somayeh VafaeiSomayeh Vafaei
Somayeh Vafaei
AZAngelina O. Zekiy
Angelina O. Zekiy
RKRamadhan Ado Khanamir
Ramadhan Ado Khanamir
Burhan Abdullah ZamanBurhan Abdullah Zaman
Burhan Abdullah Zaman
AGArman Ghayourvahdat
Arman Ghayourvahdat
MZMajid Zamani
Majid Zamani
Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects. Though, tumor inherent or acquired resistance to ICIs accompanied with treatment-related toxicities hamper their clinical utility. Overall, about 60–70% of patients (e.g., melanoma and lung cancer) who received ICIs show no objective response to intervention. The resistance to ICIs mainly caused by alterations in the tumor microenvironment (TME), which in turn, supports angiogenesis and also blocks immune cell antitumor activities, facilitating tumor cells' evasion from host immunosurveillance. Thereby, it has been supposed and also validated that combination therapy with ICIs and other therapeutic means, ranging from chemoradiotherapy to targeted therapies as well as cancer vaccines, can capably compromise tumor resistance to immune checkpoint blocked therapy. Herein, we have focused on the therapeutic benefits of ICIs as a groundbreaking approach in the context of tumor immunotherapy and also deliver an overview concerning the therapeutic influences of the addition of ICIs to other modalities to circumvent tumor resistance to ICIs.

1 September 2019 in Life Sciences
Verified
Journal Article
Closed access
YYYoda Yaghoubi
Yoda Yaghoubi
AMAliAkbar Movassaghpour
AliAkbar Movassaghpour
MZMajid Zamani
Majid Zamani
MTMehdi Talebi
Mehdi Talebi
AMAmir Mehdizadeh
Amir Mehdizadeh
MYMehdi Yousefi
Mehdi Yousefi

19 August 2022 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
HYhadi yari
hadi yari
MMMaria V. Mikhailova
Maria V. Mikhailova
MMMahsa Mardasi
Mahsa Mardasi
MJMohsen Jafarzadehgharehziaaddin
Mohsen Jafarzadehgharehziaaddin
SSSomayeh Shahrokh
Somayeh Shahrokh
SASamira Alesaeidi
Samira Alesaeidi
Accumulating proofs signify that pleiotropic effects of mesenchymal stromal cells (MSCs) are not allied to their differentiation competencies but rather are mediated mainly by the releases of soluble paracrine mediators, making them a reasonable therapeutic option to enable damaged tissue repair. Due to their unique immunomodulatory and regenerative attributes, the MSC-derived exosomes hold great potential to treat neurodegeneration-associated neurological diseases. Exosome treatment circumvents drawbacks regarding the direct administration of MSCs, such as tumor formation or reduced infiltration and migration to brain tissue. Noteworthy, MSCs-derived exosomes can cross the blood–brain barrier (BBB) and then efficiently deliver their cargo (e.g., protein, miRNAs, lipid, and mRNA) to damaged brain tissue. These biomolecules influence various biological processes (e.g., survival, proliferation, migration, etc.) in neurons, oligodendrocytes, and astrocytes. Various studies have shown that the systemic or local administration of MSCs-derived exosome could lead to the favored outcome in animals with neurodegeneration-associated disease mainly by supporting BBB integrity, eliciting pro-angiogenic effects, attenuating neuroinflammation, and promoting neurogenesis in vivo. In the present review, we will deliver an overview of the therapeutic benefits of MSCs-derived exosome therapy to ameliorate the pathological symptoms of acute and chronic neurodegenerative disease. Also, the underlying mechanism behind these favored effects has been elucidated.

1 August 2020 in European Journal of Cell Biology
Verified
Journal Article
Closed access
ASAli Shariati
Ali Shariati
RNReza Nemati
Reza Nemati
YSYasin Sadeghipour
Yasin Sadeghipour
YYYoda Yaghoubi
Yoda Yaghoubi
RBReza Baghbani
Reza Baghbani
AHAli Hassanzadeh
Ali Hassanzadeh

26 May 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
STShirin Tavakoli
Shirin Tavakoli
HJHamid Reza Ghaderi Jafarbeigloo
Hamid Reza Ghaderi Jafarbeigloo
ASAli Shariati
Ali Shariati
AJAfsaneh Jahangiryan
Afsaneh Jahangiryan
FJFaezeh Jadidi
Faezeh Jadidi
ANAdel Naimi
Adel Naimi

25 March 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MZMajid Zamani
Majid Zamani
YYYoda Yaghoubi
Yoda Yaghoubi
AMAliakbar Movassaghpour
Aliakbar Movassaghpour
KSKazem Shakouri
Kazem Shakouri
AMAmir Mehdizadeh
Amir Mehdizadeh
MYMehdi Yousefi
Mehdi Yousefi